S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
NASDAQ:ABCL

AbCellera Biologics (ABCL) Stock Forecast, Price & News

$6.80
-0.11 (-1.59%)
(As of 05/26/2023 08:46 PM ET)
Compare
Today's Range
$6.35
$6.96
50-Day Range
$5.66
$7.62
52-Week Range
$5.53
$14.97
Volume
4.89 million shs
Average Volume
1.91 million shs
Market Capitalization
$1.96 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.57

AbCellera Biologics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
276.1% Upside
$25.57 Price Target
Short Interest
Bearish
13.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.99mentions of AbCellera Biologics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Acquiring Shares
$1.10 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.57) to ($0.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

583rd out of 1,010 stocks

Pharmaceutical Preparations Industry

290th out of 494 stocks


ABCL stock logo

About AbCellera Biologics (NASDAQ:ABCL) Stock

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

ABCL Stock News Headlines

AbCellera Biologics (ABCL) Gets a Buy from Berenberg Bank
Wall Street Veteran: "A New Wave of Crashes Will Rock US Stocks"
He called the 2020 crash and 2022 bear market. Now he says the next 90 days will determine your financial life for a decade. It doesn't matter if you have money in stocks right now, or are waiting on the sidelines. The short period we're about to enter changes everything.
AbCellera to make C$701 million co-investment in Canada
AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 7.7%
Wall Street Veteran: "A New Wave of Crashes Will Rock US Stocks"
He called the 2020 crash and 2022 bear market. Now he says the next 90 days will determine your financial life for a decade. It doesn't matter if you have money in stocks right now, or are waiting on the sidelines. The short period we're about to enter changes everything.
AbCellera Biologics (NASDAQ: ABCL)
Q1 2023 Abcellera Biologics Inc Earnings Call
See More Headlines
Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

ABCL Company Calendar

Last Earnings
5/04/2023
Today
5/29/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABCL
Fax
N/A
Employees
386
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.57
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+276.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$158.52 million
Pretax Margin
-22.02%

Debt

Sales & Book Value

Annual Sales
$485.42 million
Cash Flow
$0.67 per share
Book Value
$4.19 per share

Miscellaneous

Free Float
201,243,000
Market Cap
$1.96 billion
Optionable
Not Optionable
Beta
-0.12

Key Executives

  • Dr. Carl L.G. Hansen Ph.D. (Age 48)
    CEO, Pres & Chairperson
    Comp: $616.66k
  • Mr. Andrew Booth M.B.A.Mr. Andrew Booth M.B.A. (Age 49)
    Chief Financial Officer
    Comp: $563.57k
  • Dr. Veronique Lecault Ph.D. (Age 38)
    COO & Director
    Comp: $563.57k
  • Mr. Tryn T. Stimart Esq. (Age 53)
    J.D., Chief Legal Officer, Chief Compliance Officer & Corp. Sec.
    Comp: $563.8k
  • Dr. Ester Falconer Ph.D. (Age 48)
    Chief Technology Officer
  • Mr. Bo Barnhart Ph.D.
    Scientific Director
  • Ms. Tiffany Chiu B.Sc.
    Ph.D., VP of Communications
  • Mr. Murray McCutcheon Ph.D.
    Sr. VP of Corp. Devel.
  • Alexandra Weirich M.Sc.
    Mang. of Marketing & Communications
  • Caitlin Webster CIPD
    M.Sc., Sr. Mang. of People & Culture













ABCL Stock - Frequently Asked Questions

Should I buy or sell AbCellera Biologics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABCL shares.
View ABCL analyst ratings
or view top-rated stocks.

What is AbCellera Biologics' stock price forecast for 2023?

8 analysts have issued 12 month price objectives for AbCellera Biologics' shares. Their ABCL share price forecasts range from $15.00 to $34.00. On average, they expect the company's share price to reach $25.57 in the next year. This suggests a possible upside of 276.1% from the stock's current price.
View analysts price targets for ABCL
or view top-rated stocks among Wall Street analysts.

How have ABCL shares performed in 2023?

AbCellera Biologics' stock was trading at $10.13 at the beginning of 2023. Since then, ABCL stock has decreased by 32.9% and is now trading at $6.80.
View the best growth stocks for 2023 here
.

Are investors shorting AbCellera Biologics?

AbCellera Biologics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 26,620,000 shares, an increase of 8.5% from the April 30th total of 24,530,000 shares. Based on an average daily trading volume, of 1,970,000 shares, the days-to-cover ratio is currently 13.5 days. Approximately 13.5% of the shares of the company are short sold.
View AbCellera Biologics' Short Interest
.

When is AbCellera Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ABCL earnings forecast
.

How were AbCellera Biologics' earnings last quarter?

AbCellera Biologics Inc. (NASDAQ:ABCL) released its quarterly earnings results on Thursday, May, 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.02. The firm had revenue of $12.20 million for the quarter, compared to analyst estimates of $12.11 million. AbCellera Biologics had a negative net margin of 27.71% and a negative trailing twelve-month return on equity of 4.09%. The firm's revenue for the quarter was down 96.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.54 EPS.

When did AbCellera Biologics IPO?

(ABCL) raised $356 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets served as the underwriters for the IPO.

What is AbCellera Biologics' stock symbol?

AbCellera Biologics trades on the NASDAQ under the ticker symbol "ABCL."

Who are AbCellera Biologics' major shareholders?

AbCellera Biologics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (6.89%), BlackRock Inc. (4.74%), Credit Suisse AG (1.60%), State Street Corp (1.17%), Federated Hermes Inc. (1.01%) and Renaissance Technologies LLC (0.97%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault.
View institutional ownership trends
.

How do I buy shares of AbCellera Biologics?

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbCellera Biologics' stock price today?

One share of ABCL stock can currently be purchased for approximately $6.80.

How much money does AbCellera Biologics make?

AbCellera Biologics (NASDAQ:ABCL) has a market capitalization of $1.96 billion and generates $485.42 million in revenue each year. The company earns $158.52 million in net income (profit) each year or ($0.18) on an earnings per share basis.

How many employees does AbCellera Biologics have?

The company employs 386 workers across the globe.

How can I contact AbCellera Biologics?

The official website for the company is www.abcellera.com. The company can be reached via phone at 604-559-9005 or via email at ir@abcellera.com.

This page (NASDAQ:ABCL) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -